92 related articles for article (PubMed ID: 30409719)
1. Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma.
Smith SD; Gandhy S; Gopal AK; Reddy P; Shadman M; Till BG; Lynch RC; Kanan S; Cowan A; Low L; Hill BT
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):48-52. PubMed ID: 30409719
[TBL] [Abstract][Full Text] [Related]
2. The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.
Fischer L; Jiang L; Dürig J; Schmidt C; Stilgenbauer S; Bouabdallah K; Solal-Celigny P; Scholz CW; Feugier P; de Wit M; Trappe RU; Hallek M; Graeven U; Hänel M; Hoffmann M; Delwail V; Macro M; Greiner J; Giagounidis AAN; Dargel B; Durot E; Foussard C; Silkenstedt E; Weigert O; Pott C; Klapper W; Hiddemann W; Unterhalt M; Hoster E; Ribrag V; Dreyling M
Leukemia; 2024 Jun; 38(6):1307-1314. PubMed ID: 38678093
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma.
van Keep M; Gairy K; Seshagiri D; Thilakarathne P; Lee D
BMC Cancer; 2016 Aug; 16(1):598. PubMed ID: 27488675
[TBL] [Abstract][Full Text] [Related]
4. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma.
Lee HJ; Romaguera JE; Feng L; Desai AP; Zhang L; Fanale M; Samaniego F; Hagemeister FB; Fayad LE; Rodriguez MA; Medeiros JL; Hartig K; Nomie K; Ahmed M; Badillo M; Ye H; Oki Y; Lin P; Nastoupil L; Westin J; Wang M
Oncologist; 2017 May; 22(5):549-553. PubMed ID: 28408615
[TBL] [Abstract][Full Text] [Related]
5. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.
Ruan J; Martin P; Coleman M; Furman RR; Cheung K; Faye A; Elstrom R; Lachs M; Hajjar KA; Leonard JP
Cancer; 2010 Jun; 116(11):2655-64. PubMed ID: 20235190
[TBL] [Abstract][Full Text] [Related]
6. Real-world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis.
Yang P; Cai QQ; Zhang W; Liu SZ; Liu H; Sun XH; Dong YJ; Xiao XB; Wang JW; Li ZL; Huang WR; Li LH; Bao HZ; Yang W; Wang YL; Wang SY; He J; Li XL; Liu AC; Jing HM
Cancer Med; 2023 Jun; 12(12):13204-13216. PubMed ID: 37148540
[TBL] [Abstract][Full Text] [Related]
7. The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial.
Rule S; Smith P; Johnson PW; Bolam S; Follows G; Gambell J; Hillmen P; Jack A; Johnson S; Kirkwood AA; Kruger A; Pocock C; Seymour JF; Toncheva M; Walewski J; Linch D
Haematologica; 2016 Feb; 101(2):235-40. PubMed ID: 26611473
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in
Lew TE; Cliff ERS; Dickinson M; Tam CS; Seymour JF; Blombery P; Bajel A; Ritchie D; Khot A
Leuk Lymphoma; 2023; 64(11):1792-1800. PubMed ID: 37531077
[TBL] [Abstract][Full Text] [Related]
9. Secondary malignancies among mantle cell lymphoma patients.
Abalo KD; Smedby KE; Ekberg S; Eloranta S; Pahnke S; Albertsson-Lindblad A; Jerkeman M; Glimelius I
Eur J Cancer; 2023 Dec; 195():113403. PubMed ID: 37952281
[TBL] [Abstract][Full Text] [Related]
10. Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents.
Buege MJ; Kumar A; Dixon BN; Tang LA; Pak T; Orozco J; Peterson TJ; Maples KT
Ann Pharmacother; 2020 Sep; 54(9):879-898. PubMed ID: 32079411
[No Abstract] [Full Text] [Related]
11. SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024.
Ip A; Della Pia A; Goy AH
Clin Lymphoma Myeloma Leuk; 2024 Feb; ():. PubMed ID: 38493059
[TBL] [Abstract][Full Text] [Related]
12. Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma.
Villa D; Jiang A; Visco C; Crosbie N; McCulloch R; Buege MJ; Kumar A; Bond DA; Paludo J; Maurer MJ; Thanarajasingam G; Lewis KL; Cheah CY; Baech J; El-Galaly TC; Kugathasan L; Scott DW; Gerrie AS; Lewis D
Blood Adv; 2023 Aug; 7(16):4576-4585. PubMed ID: 37307169
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab.
Ramsower CA; Rosenthal A; Robetorye RS; Mwangi R; Maurer M; Villa D; McDonnell T; Feldman A; Cohen JB; Habermann T; Campo E; Clot G; Bühler MM; Kulis M; Martin-Subero JI; Giné E; Cook JR; Hill B; Raess PW; Beiske KH; Reichart A; Hartmann S; Holte H; Scott D; Rimsza L
Br J Haematol; 2024 Jan; 204(1):160-170. PubMed ID: 37881141
[TBL] [Abstract][Full Text] [Related]
14. Frontline therapy and role of high-dose consolidation in mantle cell lymphoma.
Rule S
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):419-424. PubMed ID: 27913510
[TBL] [Abstract][Full Text] [Related]
15. Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy.
Ye H; Desai A; Huang S; Jung D; Champlin R; Zeng D; Yan F; Nomie K; Romaguera J; Ahmed M; Wang ML
J Exp Clin Cancer Res; 2018 Jul; 37(1):150. PubMed ID: 30005678
[TBL] [Abstract][Full Text] [Related]
16. Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs.
Squires P; Puckett J; Ryland KE; Kamal-Bahl S; Raut M; Doshi JA; Huntington SF
Leuk Lymphoma; 2023; 64(11):1752-1770. PubMed ID: 37497877
[TBL] [Abstract][Full Text] [Related]
17. [Progressive necrotizing xanthogranuloma in both eyes: a case report].
Yang WY; Chen H; Ren RX; Xie Y; Wang JH; Wu S; Ji M
Zhonghua Yan Ke Za Zhi; 2024 May; 60(5):447-450. PubMed ID: 38706083
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma.
Sidiqi MH; Aljama MA; Bin Riaz I; Dispenzieri A; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Rajkumar SV; Kumar SK; Gertz MA
Blood Cancer J; 2018 Nov; 8(11):106. PubMed ID: 30409963
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis.
Rule S; Dreyling M; Goy A; Hess G; Auer R; Kahl B; Hernández-Rivas JÁ; Qi K; Deshpande S; Parisi L; Wang M
Haematologica; 2019 May; 104(5):e211-e214. PubMed ID: 30442728
[No Abstract] [Full Text] [Related]
20. Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR.
Dimopoulos M; Siegel D; White DJ; Boccia R; Iskander KS; Yang Z; Kimball AS; Mezzi K; Ludwig H; Niesvizky R
Blood; 2019 Jan; 133(2):147-155. PubMed ID: 30478094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]